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Abstract
Background: Filarial parasites (e.g., Brugia malayi, Onchocerca volvulus, and Wuchereria bancrofti) are causative agents of
lymphatic filariasis and onchocerciasis, which are among the most disabling of neglected tropical diseases. There is an
urgent need to develop macro-filaricidal drugs, as current anti-filarial chemotherapy (e.g., diethylcarbamazine [DEC],
ivermectin and albendazole) can interrupt transmission predominantly by killing microfilariae (mf) larvae, but is less effective
on adult worms, which can live for decades in the human host. All medically relevant human filarial parasites appear to
contain an obligate endosymbiotic bacterium, Wolbachia. This alpha-proteobacterial mutualist has been recognized as a
potential target for filarial nematode life cycle intervention, as antibiotic treatments of filarial worms harboring Wolbachia
result in the loss of worm fertility and viability upon antibiotic treatments both in vitro and in vivo. Human trials have
confirmed this approach, although the length of treatments, high doses required and medical counter-indications for young
children and pregnant women warrant the identification of additional anti-Wolbachia drugs.
Methods and Findings: Genome sequence analysis indicated that enzymes involved in heme biosynthesis might constitute
a potential anti-Wolbachia target set. We tested different heme biosynthetic pathway inhibitors in ex vivo B. malayi viability
assays and report a specific effect of N-methyl mesoporphyrin (NMMP), which targets ferrochelatase (FC, the last step). Our
phylogenetic analysis indicates evolutionarily significant divergence between Wolbachia heme genes and their human
homologues. We therefore undertook the cloning, overexpression and analysis of several enzymes of this pathway
alongside their human homologues, and prepared proteins for drug targeting. In vitro enzyme assays revealed a ,600-fold
difference in drug sensitivities to succinyl acetone (SA) between Wolbachia and human 59-aminolevulinic acid dehydratase
(ALAD, the second step). Similarly, Escherichia coli hemH (FC) deficient strains transformed with human and Wolbachia FC
homologues showed significantly different sensitivities to NMMP. This approach enables functional complementation in E.
coli heme deficient mutants as an alternative E. coli-based method for drug screening.
Conclusions: Our studies indicate that the heme biosynthetic genes in the Wolbachia of B. malayi (wBm) might be essential
for the filarial host survival. In addition, the results suggest they are likely candidate drug targets based upon significant
differences in phylogenetic distance, biochemical properties and sensitivities to heme biosynthesis inhibitors, as compared
to their human homologues.
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Introduction
Human filarial nematodes affect more than 150 million people
worldwide with 1 billion people at risk in over 80 countries, and
lead to some of the most debilitating tropical diseases, including
elephantiasis and African river blindness [1,2]. The current anti-
filarial treatments e.g. DEC, ivermectin, albendazole (all suitable
for lymphatic filariasis; ivermectin for onchocerciasis) interrupt the
cycle of transmission of the causative filarial parasites Brugia malayi,
Onchocerca volvulus and Wuchereria bancrofti, by predominantly killing
microfilaria. However, a lower activity against adult worms, which
can survive in human hosts for up to decades, is known. DEC and
albendazole produce macrofilaricidal activity only after repeated
rounds of mass drug administration (MDA) [3]. Since the current
treatments have to be administered annually on a community-
wide basis for many years to break the infection cycle, and drug
resistance may be emerging [4,5], there is still an urgent need to
develop novel drugs (particularly macrofilaricidal). Numerous lines
of evidence, in both laboratory and human trials, show that
depletion of Wolbachia in filarial parasites by antibiotics (e.g.
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affecting embryogenesis, mf output and worm development
[6,7,8,9,10,11,12,13]. These studies indicate that these vertically
transmitted Wolbachia endosymbionts are indispensible for their
filarial hosts and represent a promising therapeutic strategy for
filariasis control.
Comparative analysis of available genomic sequences for
Wolbachia (wBm, GenBank accession no. AE017321) and its B.
malayi nematode host (GenBank accession no. EF588824 to
EF588901) provides insight into metabolic pathways that might
contribute to the mutualistic symbiotic relationship [14]. This
approach can be used to aid identification of potential anti-filarial
drug targets. One biochemical pathway identified as potentially
important in the symbiotic relationship between wBm and its
nematode host is heme biosynthesis. Heme, an iron-containing
tetrapyrrole, is an essential cofactor for many proteins such as
cytochromes, hemoglobins, peroxidases, and catalases, which are
involved in a wide range of critical biological processes, including
oxidative metabolism and electron transport. All but one of the
C4-type heme biosynthetic genes are readily identified from the
wBm genome (Fig. 1). The only missing step, protoporphyrinogen-
IX oxidase (PPO/hemG), has not been identified in many heme-
producing bacteria [15]. However, all but one heme biosynthetic
gene (FC/hemH, ferrochelatase, the last step in heme biosynthesis)
is absent in the B. malayi genome [16], implying filarial nematodes
are incapable of de novo heme biosynthesis, a condition that seems
to be characteristic of all or most nematodes, including
Caenorhabditis elegans [17]. Filarial worms presumably salvage
heme/intermediates from their surroundings and/or acquire them
from their Wolbachia endosymbionts. Heme deprivation may at
least partially account for the effects caused by elimination of wBm
following antibiotic treatment of filarial worms. For example, it is
already known that antibiotic treatment disrupts the L4 to L5 molt
in B. pahangi [18]. Furthermore, heme-containing enzymes such as
peroxidases have critical functions in the molting of C. elegans and
orthologs exist in B. malayi [19,20,21]. In this report, we indicate
that Wolbachia heme biosynthesis likely contributes to filarial worm
survival and thus could be a potential anti-filarial drug target
pathway.
Materials and Methods
Cloning, expression and purification of human and
Wolbachia heme biosynthetic enzymes
Human heme gene cDNA clones were purchased from the
Invitrogen human cDNA clone collection, except for the 59-
aminolevulinic acid synthetase cDNA clone which was purchased
Figure 1. Schematic diagram of the heme biosynthetic
pathway. The text in the boxes indicates the eukaryotic/prokaryotic/
Wolbachia gene name. The asterisk indicates the gene missing in
Wolbachia genome (PPO). ALAS, 5-aminolevulinate synthase (EC
2.3.1.37); ALAD, 5-aminolevulinate dehydratase (also known as PBGS,
porphobilinogen synthase, EC 4.2.1.24); PBGD, porphobilinogen deam-
inase (EC 4.1.3.8); UROS, uroporphyrinogen-III synthase (EC 4.2.1.75);
UROD, uroporphyrinogen-III decarboxylase (EC 4.1.1.37); CPO, copro-
porphyrinogen-IX oxidase (EC 1.11.1.10); PPO, protoporphyrinogen-IX
oxidase (EC 1.3.3.4); FC, ferrochelatase (EC 4.99.1.1); SA, ALAD inhibitor
Succinyl acetone; NMMP, FC inhibitor N-methyl mesoporphyrin.
doi:10.1371/journal.pntd.0000475.g001
Author Summary
Human filarial nematodes are causative agents of elephan-
tiasis and African river blindness, which are among the
most debilitating tropical diseases. Currently used drugs
mainly affect microfilariae (mf) and have less effect on
adult filarial nematodes, which can live in the human host
for more than a decade. Filariasis drug control strategy
relies on recurrent mass drug administration for many
years. Development of novel drugs is also urgently needed
due to the threat of drug resistance occurrence. Most
filarial worms harbor an obligate endosymbiotic bacteri-
um, Wolbachia, whose presence has been identified as a
potential drug target. Comparative genomics had sug-
gested Wolbachia heme biosynthesis as a potential drug
target, and we present an analysis of selected enzymes
alongside their human homologues from several different
aspects—gene phylogenetic analyses, in vitro enzyme
kinetic and inhibition assays and heme-deficient E. coli
complementation assays. We also conducted ex vivo Brugia
malayi viability assays using heme pathway inhibitors.
These experiments demonstrate that heme biosynthesis
could be critical for filarial worm survival and thus is a
potential anti-filarial drug target set.
Wolbachia Heme Biosynthesis Pathway
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TRS Labs, Athens, GA. B. malayi DNA (including Wolbachia DNA)
was extracted using DNeasy extraction (Qiagen) according to the
manufacturer’s protocol. Based on available human, Wolbachia and
E. coli sequences in the NCBI database, primers were designed
with restriction endonuclease sites (Table S1) and used for full-
length open reading frame (ORF) amplification by PCR with
Phusion polymerase (New England Biolabs, NEB). After purifica-
tion by QIAquick PCR purification (Qiagen) and digestion with
corresponding restriction endonucleases (NEB), resulting PCR
products were cloned into the pET21a+ vector (Novagen) for
protein expression with a C-terminal 6XHis-tag. Correct clones
were first identified by lysed-colony PCR and then verified by
DNA sequencing. For improving protein expression and solubility,
human 59-aminolevulinic acid dehydratase (ALAD), Wolbachia
porphobilinogen deaminase (PBGD) and Wolbachia ferrochelatase
(FC) genes were codon-optimized by gene re-synthesis using
DNAworks oligonucleotide designing software [22] and USER
cloning methods [23].
All cloned heme genes were expressed in T7 Express competent
E. coli (NEB), either with or without the RIL plasmid (Stratagene)
which encodes E. coli rare tRNAs for arginine, isoleucine and
leucine. Protein expression was induced with starting OD600 0.3–
0.4, 10–100 mM isopropyl b-D-thiogalactopyranoside (IPTG,
Sigma), 18–48 hours at 14–16uC. The 6XHis-tagged proteins
were purified under native conditions, using a nickel resin (Qiagen)
according to a modified manufacturer’s protocol. Buffers (100 mM
Tris-HCl pH 8.0, 300 mM NaCl) containing different concentra-
tions of imidazole (10–20 mM, 40–50 mM and 250 mM) were
used as the lysis, wash and elution buffers, respectively. Purity of
the proteins was verified on 4–20% SDS-PAGE gels (Invitrogen)
and protein concentrations were measured on a Nanodrop ND-
1000 (Thermo Scientific). Proteins were stored at 280uC in 10%
glycerol for long-term storage or stored at 4uC for no more than 1
month for further analysis.
Phylogenetic analysis
Homologous protein sequences were retrieved from the NCBI
database via protein-protein BLAST similarity searches and were
aligned using CLUSTAL 61.83 [24]. The sequence alignments
were further refined manually after the removal of large gaps and
evolutionarily diverse regions. Based on protein sequence
alignments, gene phylogenies for the B. malayi Wolbachia heme
synthesis genes were derived from both Bayesian inference (BI)
[25] and Maximum likelihood (ML) [26] methods. ML trees were
constructed by the PROML programs of PHYLIP package
version 3.65 [27] with global rearrangements and randomized
input order options in conjunction with estimated parameter
gamma and the proportion of invariable sites obtained from
TREE-PUZZLE 5.1 [28] calculation, in which Quartet puzzling
maximum likelihood (QP) analysis was carried out employing the
JTT-f amino acid substitution probability model with a mixed
eight category gamma+invariable-sites model of rate heterogeneity
and 10,000 puzzling steps. ML analyses were performed by
subsequent applications of SEQBOOT (100 replicates), PROML
and CONSENSE. BI analyses were conducted with randomly
produced starting trees, JTT amino acid substitution frequencies,
four category gamma+invariable-sites model, 200,000 generations
of searches. Posterior possibilities for the best trees were calculated
using a 50% majority rule.
B. malayi worm ex vivo motility assays
Fresh live adult male and female B. malayi worms were
incubated with different concentrations of succinyl acetone (SA,
Sigma) or methyl mesoporphyrin (NMMP, Frontier Scientific) (3
replicates/experiment, 1 adult female or 3 adult males/replicate,
experiment repeated three times), which target ALAD and FC,
respectively. Worms were cultured in RPMI-1640 with 2 mM
glutamine, 25 mM HEPES (Gibco) with 10% Fetal Calf Serum
(Gibco) and 100 U/ml streptomycin, 100 mg/ml penicillin,
0.25 mg/ml amphotericin B (Sigma). Medium was changed every
2 days. SA was freshly made in water at a concentration of
500 mM before use. Both NMMP and hemin (Frontier Scientific)
were freshly prepared as 5 mM stock concentrations in 50%
ethanol containing 0.02 N NaOH. In NMMP tests, control worms
were cultured in medium containing 1% ethanol and 0.0004 N
NaOH (‘‘solvent only’’) with and without 100 mM hemin. Motility
was measured daily (similar to the method used by Rao et al [11])
as 0, no motility; 1, slight movement clearly observed under
microscope; 2, minor movement readily observed by eye; 3, non-
continual moderate movement; 4, continual moderate movement;
5, continual active movement.
C. elegans growth assays
C. elegans Bristol N2 was cultured and maintained according to
standard protocols [29]. Drug testing was performed as follows.
Eggs were extracted from gravid hermaphrodites using alkaline
hypochlorite treatment followed by extensive washes in M9 buffer
(22 mM KH2PO4,4 2 m MN a 2HPO4, 86 mM NaCl, 1 mM
MgSO4) [29]. Eggs were allowed to hatch overnight in S-basal
buffer (0.1 M NaCl, 0.05 M KH2PO4 pH 6, 5 mg/ml cholester-
ol). The concentration of first-stage larvae (L1) was adjusted to
obtain an average of 5 to 6 live animals per well. Pre-grown
concentrated E. coli OP50 was added as a food source. The
compounds to be tested were added at the appropriate
concentration. Worms were cultured in 96-well plates (NUNC,
Rochester, NY) in a 100 ml volume for three days at 20uC.
Twenty-four wells were cultured for each compound at a given
concentration. Only one generation was followed. The number of
parental animals reaching adulthood was scored.
Enzyme assays
Enzyme activities were assayed using purified recombinant C-
terminal 6XHis-tagged Wolbachia and human ALAD proteins
(wALAD & hALAD) at 37uC for 15–30 min. The enzyme
reactions were carried out in 100 mM Bis-Tris Propane (BTP)
buffer (Sigma, pH range 6.5–9.5) containing 1 mg protein, 5 mM
substrate 59-aminolevulinic acid (ALA) (Sigma) and 10 mM b-
mercaptoethanol (Sigma) unless otherwise stated, in a total volume
of 100 ml. All assays were initiated by the addition of ALA after
enzyme pre-incubation for 20–30 min with various metal ions (e.g.
Zn
2+,M g
2+) and/or other reagents (e.g. the metal ion chelator
EDTA, specific enzyme inhibitor SA). After determining optimal
reaction pH, enzyme assays were further conducted in the
presence of different concentrations of substrate ALA (for
determination of Km and Vmax) or inhibitor SA (for calculation
of EC50). The reaction was stopped by mixing with an equal
volume of stop buffer (0.1 M HgCl2 in 12% Trichloroacetic acid)
followed by the addition of 800 ml modified Ehrlich reagent for
10 min [30]. The product porphobilinogen (PBG) was subse-
quently estimated by measuring the absorbance at OD555. The
molar extinction coefficient for PBG (60,200 M
21 cm
21) was used
in calculation of PBG concentration (mmol PBG/mg of protein/h).
Complementation assays in E. coli
E. coli hemB (ALAD) mutant strain RP523 [31] and HemD
(Uroporphyrinogen III synthase, UROS) deletion mutation strain
SASZ31 were obtained from the E. coli Genetic Stock Center
Wolbachia Heme Biosynthesis Pathway
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SASX38 [32] and hemH (FC) deletion strain VS200 [33] were
generously provided by Dr. Harry A. Dailey, University of
Georgia. The pET21a+ vectors carrying the corresponding
human, Wolbachia and E. coli heme gene inserts were transformed
into the above-mentioned E. coli mutant strains, both with and
without RIL plasmid co-transformation alongside a vector only
control, and with appropriate antibiotic selection. Transformants
were selected on 20 mM hemin-containing LB plates with
appropriate antibiotics and incubated at 37uC overnight. The
selected transgenic clones were further tested on LB plates with no
hemin addition.
E. coli-based growth assays
E. coli hemH mutants containing human, Wolbachia or E. coli FC
genes, were used in growth assays. The fresh transgenic E. coli
mutants (grown to 0.6–0.8 OD600) were diluted to 0.01 OD600
before initiating growth assays in the presence or absence of
different concentrations of the specific FC inhibitor, NMMP in LB
medium. The E. coli cells were grown in a 30uC shaker (180 rpm)
for 3 h before estimating the cell growth level by measuring the
final OD600 values. The final cell density for the untreated controls
varied from 0.4 to 1.0 OD600. Relative cell density was taken as a
measure of toxicity. The average cell growth ratio (final OD600/
0.01) for untreated control is set at 1.0.
Results
Phylogenetic analyses reveal significant evolutionary
divergence between Wolbachia and human heme
biosynthesis gene homologues
Based upon genomic DNA sequence analyses, both humans and
Wolbachia share the C4-type heme biosynthetic pathway, usually
consisting of eight components (Fig. 1) and phylogenies inferred by
both ML and BI analyses indicate a deep evolutionary distance
existing between homologues in this pathway. Sequences for all
heme biosynthetic enzymes (except for the missing PPO gene)
were obtained by database queries from diverse organisms (17–30
species, with exclusion of archaeal sequences due to their extreme
divergence). They were aligned using ClustalX (with manual
refinement). Conserved regions (157–312 sites) were used for
phylogenetic reconstruction. The unrooted gene trees (except for
ALAS), presented in Fig. 2 and Fig. S1, show that the gene
homologues from both nematode and insect Wolbachia consistently
group together and mostly within the Rickettsia subgroup of the
alpha-proteobacterial cluster, sharing high amino acid sequence
Figure 2. Gene phylogeny of ALAD and FC. A) ALAD, B) FC. The scaled Maximum likelihood (ML) consensus trees were inferred by ProML
program of PHYLIP 3.65 package [27]. Two methods – Bayesian inference (BI) and ML analyses were used in gene phylogeny reconstruction and
yielded similar tree topologies (details see Materials and Methods). The supporting values shown at nodes were obtained from ML and BI analyses,
respectively and the values below 50% indicated by hyphens. The branch length scale shown below ML tree represents estimated substitutions per
site. Available GenBank accession numbers follow the corresponding sequences. The asterisk indicates sequences retrieved from the organism’s
genome data; details are listed in the Text S1.
doi:10.1371/journal.pntd.0000475.g002
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malayi Wolbachia heme synthesis genes only share 22–34%
identities (29–53% similarities) with their human homologues.
Among the seven identified components of Wolbachia heme
pathway (Fig. 1), two were of particular interest (gene trees are
presented in Fig. 2) owing to their significant divergence and
biochemical properties. The ALAD gene tree shows that Wolbachia
and human homologues belong to Zn
2+-independent and Zn
2+-
dependent groups, respectively (Fig. 2A), which is confirmed by
the absence of the critical cysteine residues in the Zn
2+-binding
sites in Wolbachia ALADs, while present in human ALAD (Text
S1). Similarly, it is known that human FC contains both an N-
terminal extension (encoding a mitochondrion-targeting signal)
and a C-terminal extension (involved in formation of homodi-
mers), and harbors an [Fe-S] cluster binding site (formed by 4
cysteine residues) [34,35]. However, sequence analysis of Wolbachia
FCs revealed that they do not have any of these features (Text S1).
This is in line with the FC phylogenetic analysis that shows
significant evolutionary divergence between human and Wolbachia
FCs (Fig. 2B).
Wolbachia heme biosynthesis might be crucial for B.
malayi worm survival
Two analog inhibitors, SA (1–3 mM) and NMMP (10–
100 mM), were used in B. malayi worm ex vivo motility assays,
which specifically target ALAD and FC, respectively. The results
are shown in Fig. 3A–D. Motility was measured (similar to the
method used by Rao et al [11]). Compared to the untreated
controls, both SA and NMMP lead to significantly reduced
motilities of adult worms during the nine-day treatments,
independent of the addition of hemin to the medium (Fig. 3A–
D). The tissue/cell structure of immotile worms (scaled as 0)
seemed degenerative after treatment and no recovery was
observed even after transferring these worms to fresh medium
without inhibitor. Similar results were also observed in B. malayi mf
larvae assays (data not shown). The effect of the inhibitors on
female adult worms (Fig. 3B, D) appears more severe than that on
male adult worms (Fig. 3A, C). The free-living nematode C. elegans
was used as a worm control as it lacks the heme biosynthetic
pathway and does not harbor an obligate endosymbiont, so has to
salvage heme from the medium for viability [17]. In the presence
of hemin, NMMP (10–100 mM) did not affect the growth of C.
elegans larvae into adults (Fig. 3E) or worm fertility (data not shown)
as expected. However, SA (1–3 mM) appeared to have a non-
specific inhibitory effect on C. elegans larval development (Fig. 3E)
and resulted in 100% sterility even at the lowest concentration
tested (data not shown).
Biochemical characterization of purified recombinant
Wolbachia and human ALAD enzymes
cDNA clones in pET 21a+ of Wolbachia and human ALADs
were transformed into E. coli containing the RIL plasmid and
expressed as C-terminal 6XHis-tagged proteins. However, expres-
sion for hALAD was very poor, thus a codon-optimized version
was made for improvement of expression. Examples of purified
full-length C-terminal 6XHis-tagged wALAD (37.7 kDa) and
hALAD (37.4 kDa) are presented in Fig. 4.
The pH profiles (Fig. 5) for hALAD and wALAD enzyme
activities indicate an overlapped optimal pH range (pH 6.5–7.5 vs
pH 7.0–8.5). hALAD is Zn
2+-dependent. At optimal pH 7.0, its
activity is inhibited by the metal ion chelator EDTA and recovered
by addition of Zn
2+ (Fig. 6A). wALAD activity (at its optimal
pH 8.0) is also sensitive to EDTA inhibition, however, its activity is
only restored by Mg
2+ addition (Fig 6B). This suggests that wALAD
is Zn
2+-independent, which agrees with the absence of a putative
Zn
2+ binding site in wALAD, while it is present in hALAD. The
maximum activity (Vmax) of hALAD (pH 7.0) is measured as
57.862.2 mmol porphobilinogen (PBG)/mg of protein/h and the
Km value for substrate ALA is 0.3560.06 mM (Fig. S2A), while for
wALAD (pH 8.0), the Vmax and Km values are 22.561.1 mmol
PBG/mg of protein/h and 0.3260.07 mM, respectively (Fig. S2B).
hALAD activity is about 2.5 times higher than that of wALAD with
similar ALA substrate binding affinity.
SA is a specific ALAD inhibitor with different potency
depending on the particular ALAD species involved. The
sensitivities of wALAD and hALAD to SA are presented in
Fig. 7. Both enzymes could be inhibited by SA, but with strikingly
different inhibition profiles - EC50s for wALAD and hALAD were
,109 mM and ,0.18 mM, respectively, a 600 fold difference. This
likely reflects a significant structural variation between these two
enzymes.
Functional complementation of E. coli heme deficient
mutants and E. coli-based drug sensitivity assays
To test whether the cloned Wolbachia heme biosynthetic genes
are functional, we performed complementation assays using E. coli
heme deficient mutant strains (hemB, hemD, hemG and hemH). These
assays complement the in vitro enzyme assays described above. The
corresponding Wolbachia and human heme genes, cloned in the
pET21a+ vector, were tested for activity, alongside a pET21a+
vector negative control.
An E. coli hemB mutant, transformed with the pET21a+
plasmid fails to grow on LB plates, unless hemin is added to the
media. Transformations of the E. coli hemB mutant strain with
wALAD or hALAD constructs result in strong colony growth on
LB plates without hemin addition, similar to wild type E. coli
growth, indicating functional expression of these two heme
genes in E. coli. Similar complementation was observed for E.
coli hemD and hemH mutants with Wolbachia/human UROS and
Wolbachia/human FC genes, respectively. As mentioned previ-
ously, Wolbachia PPO is still un-recognized. It has been reported
that overexpression of E. coli CPO might function as PPO [36]
and therefore we tested an E. coli hemG mutant with the wBm
CPO construct. No complementation was observed, even under
IPTG induction. As a positive control, an E. coli hemG mutant
was functionally complemented by transformation with the
human PPO construct. Our enzyme assays and E. coli
complementation tests verified that Wolbachia ALAD, UROS
and FC genes are functional. Since ALAD is the second step
and FC is the last step of the heme biosynthesis pathways, our
results indicate that Wolbachia has the ability to synthesize
endogenous heme.
FC is a potential drug target based on its evolutionary
divergence and differing protein features compared to its human
homologue. Human FC (hFC) is an [Fe-S] protein, while
Wolbachia FC (wFC) lacks [Fe-S] clusters. A potent FC inhibitor
- NMMP was used in growth inhibition assays using E. coli hemH
mutants transformed with wFC, hFC or E. coli FC (EcFC). The
growth of all transformed strains was inhibited by NMMP with
significantly different drug sensitivities (sensitivity level:
hFC.EcFC.wFC) as compared to their non-treated controls
(Fig. 8). The inhibition was readily overcome by the inclusion of
hemin in the growth medium (Fig. 8). This assay further supports
the possibility of using a rapid E. coli-based complementation assay
to screen for specific inhibitors that will differentially target the
Wolbachia heme synthesis enzymes.
Wolbachia Heme Biosynthesis Pathway
www.plosntds.org 5 July 2009 | Volume 3 | Issue 7 | e475Figure 3. Effects of succinyl acetone (SA) and N-methyl-mesoporphyrin (NMMP) on the motility of B. malayi adult worms ex vivo and
C. elegans larval growth. A) Effect of SA on B. malayi adult males, B) Effect of SA on B. malayi adult females, C) Effect of NMMP on B. malayi adult
males, D) Effect of NMMP on B. malayi adult females, E) Effects of SA and NMMP on growth of C. elegans. The scale of viability (A–D) is arbitrarily
measured by the relative motility of the adult worms: 0, no motility; 1, slight movement clearly observed under microscope; 2, minor movement
readily observed by eye; 3, non-continual moderate movement; 4, continual moderate movement; 5, continual active movement. Control B. malayi
worms (C, D) were cultured in medium containing 1% ethanol and 0.0004 N NaOH (‘‘solvent only’’) with and without 100 mM hemin. Data is compiled
from 3 independent experiments (see Materials and Methods). Control C. elegans worms (E) were grown in 1% ethanol with 0.0004 N NaOH, which
corresponds to the concentration of ethanol and NaOH present in the 100 mM NMMP test.
doi:10.1371/journal.pntd.0000475.g003
Wolbachia Heme Biosynthesis Pathway
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Anti-Wolbachia chemotherapeutic treatment is an emerging
approach for filariasis control [37]. Comparative genomic and
bioinformatic analyses are shedding light onto the mutualistic
symbiotic relationship between Wolbachia and its filarial host,
revealing essential biochemical pathways in the bacterial endo-
symbiont that might provide critical metabolites for its worm host
survival [14]. Based on our data from ex vivo worm assays,
phylogenetic analyses, gene expression and purification profiles, in
vitro enzyme assays, and E. coli complementation results, we have
evaluated the possibility of the Wolbachia heme pathway as an anti-
filarial drug target set. No heme biosynthetic genes except
ferrochelatase (FC, the last step) have been identified from the
worm host B. malayi genome sequence [16]. It appears that the
nematode is not capable of synthesizing heme de novo, and thus
may have to acquire heme from its Wolbachia endosymbiont or
salvage environmental heme or both. The motilities of both B.
malayi male and female worms are significantly reduced when
exposed to the heme biosynthesis inhibitor SA (targeting ALAD),
even in the presence of hemin in the medium (Fig. 3A–B).
However, we believe that this effect was non-specific because a
similar phenotype was observed when C. elegans, a heme
auxotroph, which does not have the biosynthetic pathway at all,
was exposed to SA (Fig. 3E), suggesting that SA may have some
unspecific effect on B. malayi. In contrast, NMMP appears to be
potent and specific in its inhibitory effect on the heme pathway,
since it has an in vivo effect on B. malayi (Fig. 3C–D), but not on C.
elegans (Fig. 3E). This inhibition can not be rescued by hemin
(Fig. 3C–D), implying that B. malayi possibly lacks the capability of
salvaging environmental heme, as has been demonstrated for C.
elegans [38]. However, it should be noted that the B. malayi genome
encodes for FC [16] and the effect of NMMP on B. malayi
ferrochelatase (BmFC) could contribute to the inhibition of the
worm viability (Wu et al, in preparation). We have no
experimental evidence for a direct effect of NMMP on Wolbachia.
Thus, the survival of B. malayi might be dependent on bacterial
derived heme from the Wolbachia heme biosynthetic pathway and/
or a functional BmFC which may utilize porphyrin intermediates
from the endosymbiont or the environment. Given the observed
differences between human and B. malayi FC proteins, specific
inhibition of nematode FC in infected humans could be a potential
drug target (Wu et al, in preparation).
Because mammals also synthesize heme via the C4-type
pathway like Wolbachia, caution is needed when considering
Wolbachia heme biosynthetic enzymes as anti-filarial drug targets.
However, phylogenetic analyses (Fig. 2 & Fig. S1) revealed that
significant evolutionary distances exist among the human and
Wolbachia heme genes (except for ALAS), as shown by their low
sequence similarities/identities (22–34%/29–53%). We corrobo-
rate these in silico studies with biochemical/pharmacological assays
by cloning the Wolbachia and human genes and expressing the
proteins. Difficulty in protein expression or purification of soluble
proteins for hALAD, wPBGD & wFC was addressed by codon
optimization. This helped improve expression levels, but still failed
to yield soluble proteins, with the exception of synthetic hALAD.
Based on the significant difference (,600 fold) in drug
sensitivities between wALAD and hALAD enzymes (Fig. 7), large
amounts of recombinant wALAD and hALAD proteins are
currently being prepared for high throughput screening as part of
anti-Wolbachia (A-WOL) drug discovery and development program
(http://www.a-wol.com). Crystal structures are available for
ALAD from human, mouse, yeast, Pseudomonas aeruginosa and
Chlorobium vibrioforme (including a structure for yeast ALAD in
complex with SA) from Protein Data Bank (PDB, http://www.
rcsb.org). With this information, structural studies of Wolbachia and
Figure 4. Purification profiles for C-terminally 6XHis-tagged
wALAD and hALAD recombinant proteins.
doi:10.1371/journal.pntd.0000475.g004
Figure 5. pH profiles for wALAD and hALAD enzyme activities. The enzyme activity is expressed as mmol PBG/mg of protein/h.
doi:10.1371/journal.pntd.0000475.g005
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observed differences in SA sensitivity and help optimize identifi-
cation of lead compounds obtained from the on-going drug
screening effort.
Functional Wolbachia heme synthesis activity for several genes
(ALAD, UROS and FC) along with their human homologues was
demonstrated by complementation tests using the corresponding
E. coli heme deficient mutants (hemB, hemD and hemH). As
mentioned above, PPO, the penultimate step in heme pathway,
is missing in Wolbachia and is unidentifiable from many other
bacterial genomes, e.g. Rickettsia [15]. The E. coli hemG mutant was
readily complemented by the human PPO gene; however, unlike
E. coli CPO, Wolbachia CPO was incapable of rescuing PPO
deficiency. Since PPO function is required for heme biosynthesis,
it is possible that an unidentified oxidase may function as PPO in
Wolbachia.
We have attempted to express and purify recombinant wFC
(codon-optimized) and hFC proteins, however the yield of pure
soluble protein was limited due to the formation of inclusion
bodies. The availability of an E. coli hemH deficient mutant and
functional complementation by wFC and hFC genes permit an
alternative E. coli-based inhibition assay and drug-screening
strategy. FC, the final step in heme biosynthesis, is responsible
for insertion of iron into protoporphyin IX (PPIX) to form heme.
NMMP is a strong PPIX analog, and competitively binds to the
FC active site with Ki values in the nM range [39]. It was reported
previously that FC enzymes could have dramatically different
sensitivities to NMMP inhibition (.1000 fold, e.g. Human FC vs
chicken FC) due to the differences existing in their active sites [40].
The E. coli hemH mutant, complemented with wFC, hFC and
EcFC, is not sensitive to NMMP when grown in the presence of
hemin. Significantly different sensitivities to NMMP were detected
between human and Wolbachia FCs in absence of hemin, with
human FC being much more sensitive. This may be accounted for
by the structural difference in their active sites. Cell-based drug
screening may help identify compounds more specifically targeting
wFC instead of hFC. FC crystal structures from several species
(human, yeast and Bacillus) are also available in PDB with a crystal
Figure 6. Effect of EDTA and metal ions on wALAD and hALAD enzyme activities. A) wALAD and B) hALAD were assayed at pH 8.0 and 7.0,
respectively. Conventional concentrations of metal ions were used in this assay. The enzyme activity is expressed as mmol PBG/mg of protein/h.
Control indicates sample without addition of extra metal ions or EDTA.
doi:10.1371/journal.pntd.0000475.g006
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silico comparative studies based on molecular modeling can be
conducted for Wolbachia and human FCs. E. coli mutants
complemented by other Wolbachia/human heme genes (ALAD,
UROS) will be used as potential screens as well for identification of
compounds specifically inhibiting selected Wolbachia heme biosyn-
thesis enzymes.
Our data suggest that the Wolbachia heme biosynthetic pathway
is a potential anti-filarial drug target due to its requirement for
survival of both Wolbachia and its filarial host. The presumptive
transporters, responsible for heme trafficking, could be drug
targets as well. However, it still remains unknown how the heme/
heme intermediates might transfer from Wolbachia to its filarial
host. No enzymes involved in traditional heme catabolism (e.g.
heme oxygenase) have been identified from the B. malayi genome
sequence. It is still an open question how transport, degradation,
and regulation of heme occur in filarial parasites.
Supporting Information
Figure S1 Gene phylogeny of ALAS, PBGD, UROS, UROD
and CPO. A) ALAS, B) PBGD, C) UROS, D) UROD, E) CPO.
The scaled Maximum likelihood (ML) consensus trees were
inferred by ProML program of PHYLIP 3.65 package [27]. Two
methods - Bayesian inference (BI) and ML analyses were used in
gene phylogeny reconstruction and yielded similar tree topologies
(details see Materials and Methods). The supporting values shown
at nodes were obtained from ML and BI analyses, respectively and
the values below 50% were indicated by hyphens. The branch
length scale shown below the ML tree represents estimated
substitutions per site. Available GenBank accession numbers
follow the corresponding sequences. * Sequences were retrieved
from the organism’s genome data directly; details are listed in the
supplementary sequence alignment file.
Found at: doi:10.1371/journal.pntd.0000475.s001 (2.06 MB TIF)
Figure S2 The Vmax and Km of the purified recombinant
wALAD and hALAD enzymes. A) wALAD and B) hALAD were
assayed at pH 8.0 and 7.0, respectively. The enzyme activity is
expressed as mmol PBG/mg of protein/h.
Found at: doi:10.1371/journal.pntd.0000475.s002 (0.13 MB TIF)
Table S1 Wolbachia, human and E. coli heme gene specific
primers were used for acquiring the full-length coding sequence by
polymerase chain reaction (PCR) amplification, and were
subsequently cloned into pET21a+ vector. Primers were designed
according to information acquired from available B. malayi,
Wolbachia (wBm), human and E. coli genome databases. Restriction
enzyme sites in primers are underlined. Abbreviations used: w:
Wolbachia, h: human, Ec: E. coli, f: forward primer, r: reverse
primer. The full names of the abbreviations for the heme
biosynthetic enzymes are listed in the caption of Figure 1.
Found at: doi:10.1371/journal.pntd.0000475.s003 (1.77 MB TIF)
Text S1 Multiple sequence alignment for heme biosynthetic
genes ALAS, ALAD, PBGD, UROS, UROD, CPO and FC.
Found at: doi:10.1371/journal.pntd.0000475.s004 (0.46 MB
DOC)
Figure 7. Biochemical characterization of recombinant wALAD
and hALAD enzymes. A) Inhibition of wALAD enzyme activity by SA,
B) Inhibition of hALAD enzyme activity by SA. The enzyme activity is
expressed as mmol PBG/mg of protein/h.
doi:10.1371/journal.pntd.0000475.g007
Figure 8. Growth inhibition assays by N-methyl mesoporphyrin
(NMMP) of E. coli HemH mutants complemented with human,
Wolbachia or E. coli FC genes. The average cell growth rate (final
OD600/0.01) for untreated control is set as 1.0.
doi:10.1371/journal.pntd.0000475.g008
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